DAY101 In Gliomas and Other Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Low-grade Glioma
Interventions
DRUG

DAY101

28 day cycle, oral, once per week

Trial Locations (15)

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Hospital, Washington D.C.

21287

Johns Hopkins University, Baltimore

32610

University of Florida, Gainesville

55404

Children's Minnesota, Minneapolis

63110

Washington University in St. Louis, St Louis

84113

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

92123

University of California, San Diego, San Diego

94158

University of California, San Francisco, San Francisco

97239

Oregon Health & Science University, Portland

98105

Seattle Children's Hospital, Seattle

02114

Massacusetts General Hospital, Boston

02115

Boston Children's Hospital, Boston

02215

Dana-Farber Cancer Institite, Boston

Sponsors
All Listed Sponsors
collaborator

PLGA Fund at Pediatric Brain Tumor Foundation

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Pacific Pediatric Neuro-Oncology Consortium

OTHER

collaborator

Team Jack Foundation

UNKNOWN

collaborator

Day One Biopharmaceuticals, Inc.

INDUSTRY

lead

Karen D. Wright, MD

OTHER

NCT03429803 - DAY101 In Gliomas and Other Tumors | Biotech Hunter | Biotech Hunter